Analysts Set GH Research PLC (NASDAQ:GHRS) Target Price at $40.38

GH Research PLC (NASDAQ:GHRS) has earned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $40.3750.

Several analysts have weighed in on GHRS shares. Citizens Jmp dropped their price objective on GH Research from $42.00 to $39.00 and set a “market outperform” rating for the company in a report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research report on Tuesday, April 21st. Cantor Fitzgerald lifted their price target on shares of GH Research from $25.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. Citigroup reaffirmed an “outperform” rating on shares of GH Research in a report on Friday, May 15th. Finally, Needham & Company LLC lifted their target price on shares of GH Research from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, March 6th.

Institutional Trading of GH Research

A number of institutional investors have recently bought and sold shares of the business. Royal Bank of Canada grew its holdings in GH Research by 43.1% during the 1st quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock worth $36,000 after acquiring an additional 780 shares during the period. Troluce Capital Advisors LLC boosted its holdings in GH Research by 165.4% during the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after buying an additional 617,260 shares during the last quarter. Renaissance Technologies LLC bought a new position in GH Research during the first quarter worth about $290,000. North Star Investment Management Corp. bought a new position in GH Research during the first quarter worth about $31,000. Finally, Avoro Capital Advisors LLC bought a new position in GH Research during the fourth quarter worth about $22,860,000. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Trading Up 1.0%

NASDAQ GHRS opened at $28.49 on Thursday. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -30.97 and a beta of 1.31. The company has a 50 day moving average of $21.93 and a 200-day moving average of $17.41. GH Research has a 1-year low of $11.32 and a 1-year high of $28.96.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.04). On average, analysts forecast that GH Research will post -1.46 earnings per share for the current year.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.